SCHEMBL7107731

SCHEMBL7107731

O=C(CNC(=O)[C@H](CO)Cc1ccccc1)OCc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.70
CYP3A4 P08684 1/20 0.70
CYP2D6 P10635 1/20 0.70
CYP2C9 P11712 1/20 0.70
CYP2C19 P33261 1/20 0.70
ABCC3 O15438 1/20 0.70
NR1I2 O75469 1/20 0.70
ABCB11 O95342 1/20 0.70
NR3C1 P04150 1/20 0.70
RARG P13631 1/20 0.70
CNR1 P21554 1/20 0.70
OPRK1 P41145 1/20 0.70
NR1H2 P55055 1/20 0.70
PPARA Q07869 1/20 0.70
NR1H3 Q13133 1/20 0.70
NR1I3 Q14994 1/20 0.70
MME P08473 5/20 0.52
ALDH1A1 P00352 3/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7105553 1.00 CYP1A2 (0.70) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL825744 0.88 CYP1A2 (0.58) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL9096963 0.88 MME (0.70) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL9997257 0.88 CYP1A2 (0.58) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL7694738 0.88 CYP1A2 (0.68) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL7107227 0.88 CYP1A2 (0.68) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10690632 0.85 CYP1A2 (0.65) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10692802 0.84 CYP1A2 (0.64) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10692742 0.83 CYP1A2 (0.66) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10038975 0.82 CYP1A2 (0.75) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161646-A2 PROCESS FOR THE PREPARATION OF ALVIMOPAN OR ITS PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF RANBAXY LABORATORIES LIMITED (IN) 2011-12-29 WO disclosed
EP-0937710-B1 Method for producing an optically active phenylpropionic acid derivative AJINOMOTO KK (JP) 2003-04-16 EP disclosed
US-6339170-B2 CONDENSATION OF 2-HYDROXYMETHYL-3-PHENYLPROPIONIC ACID AND GLYCINE BENZYL ESTER, CONVERSION OF HYDROXYL GROUP TO ELIMINATION GROUP, SUBSTITUTION BY ACETYLTHIO GROUP; ENKEPHALIN AND ACETYLCHOLINESTERASE INHIBITORS AJINOMOTO CO., INC. (JP) 2002-01-15 US disclosed
US-20010014754-A1 Method for producing optically active phenylpropionic acid derivative AJINOMOTO CO., INC. (JP) 2001-08-16 US disclosed
US-6239305-B1 REACTING A N-ACYLAMINO ACID ESTER WITH A THIOACETIC ACID AJINOMOTO CO., INC. (JP) 2001-05-29 US disclosed
US-6031121-A Method for producing optically active phenylpropionic acid derivative AJINOMOTO CO., INC. (JP) 2000-02-29 US disclosed
EP-0937710-A1 Method for producing an optically active phenylpropionic acid derivative Ajinomoto Co., Inc. (JP) 1999-08-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010014754-A1 Method for producing optically active phenylpropionic acid derivative ACE, DNPEP, AGT CYP1A2 2042/4885CYP3A4 902/4885CYP2D6 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.